1
Home
Companies

AlloVir

#9615

Rank

$44.04M

Marketcap

US United States

Country

AlloVir
Leadership team

Mr. David L. Hallal (Exec. Chairman)

Dr. Diana M. Brainard M.D. (CEO & Director)

Mr. Vikas Sinha C.A., CPA, M.B.A. (Pres, CFO & Director)

Products/ Services
Biotechnology, Clinical Trials, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Houston, Texas, United States
Established
2013
Company Registration
SEC CIK number: 0001754068
Traded as
ALVR
Social Media
URL
https://www.allovir.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
History

AlloVir was founded in 2013 as an early-stage biotechnology company focused on the development and commercialization of novel viral reduction technologies for organ transplants. It was founded by Dr. Paul Bergman and Dr. Barry Diamond and is headquartered in San Francisco, CA.

Mission
Our mission is to develop effective, affordable, lifesaving transplant therapies through delivery of innovative viral reduction therapies
Vision
To become a global leader in the field of transplant therapies by improving safety, efficacy and affordability of virus-free transplants.
Key Team

Dr. Jeroen van Beek Ph.D. (Consultant)

Mr. Agustin Melian M.D. (Advisor)

Mr. Brett R. Hagen (Chief Accounting Officer)

Mr. Dana M. Alexander M.B.A. (Sr. VP of Technical Operations)

Dr. Ann M. Leen Ph.D. (Chief Scientific Officer)

Ms. Sonia Choi (Sr. VP of Corp. Affairs & Investor Relations)

Mr. Edward Miller J.D. (Gen. Counsel & Sec.)

Recognition and Awards
In 2019 AlloVir received the Cedars-Sinai Accelerator award for excellence in healthcare technology and innovation.
References

https://www.investing.com/equities/allovir-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/viracyte

https://finance.yahoo.com/quote/alvr/

https://www.allovir.com

https://sec.report/CIK/0001754068

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

AlloVir
Leadership team

Mr. David L. Hallal (Exec. Chairman)

Dr. Diana M. Brainard M.D. (CEO & Director)

Mr. Vikas Sinha C.A., CPA, M.B.A. (Pres, CFO & Director)

Products/ Services
Biotechnology, Clinical Trials, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Houston, Texas, United States
Established
2013
Company Registration
SEC CIK number: 0001754068
Traded as
ALVR
Social Media
URL
https://www.allovir.com